PMC8071213_01
Bone metastases and PSA responses after receiving maintenance long-term multiple cycles docetaxel chemotherapy in patient 1. (A) After the 7th cycle, bone ECT showed significant remission of bone metastasis in patient 1. (i) Baseline of docetaxel administration, (ii) after 7 cycles of docetaxel administration. (B) The curve of PSA changes and chemotherapy cycles in patient 1. The patient received maintenance docetaxel chemotherapy for a total of 33 cycles. During the treatment, the PSA level of the patient was monitored regularly.
OTT-14-2797-g0001.jpg
PMC8071213_01_OTT-14-2797-g0001.jpg
f0001
By the 7th cycle, a review of his bone ECT (Figure 1A) revealed that the patients' multiple bone metastases were still stable and the patients' PSA level was 49ng/mL. By the 28th cycle, the patients' PSA level was 0.5 ng/mL (Figure 1B) and imaging examination showed significant remission.
PMC8071213_02
Bone metastases response after receiving maintenance long-term multiple cycles docetaxel chemotherapy in patient 2. After 14 cycles of docetaxel administration, bone ECT showed significant remission of bone metastasis in patient 2. (i) Baseline of docetaxel administration, (ii) after 14 cycles of docetaxel administration.
OTT-14-2797-g0002.jpg
PMC8071213_02_OTT-14-2797-g0002.jpg
f0002
Patients' bone scans were reviewed every six months, and it showed that the patients' bone metastases were reduced significantly (Figure 2).
PMC8071213_03
PSA response after receiving long-term multiple cycles docetaxel administration in patient 3. The patients received maintenance docetaxel chemotherapy for a total of 35 cycles. The PSA level of the patient was monitored regularly after docetaxel therapy. At the time of writing, the patient was still being treated with docetaxel.
OTT-14-2797-g0003.jpg
PMC8071213_03_OTT-14-2797-g0003.jpg
f0003
Since the initiation of the docetaxel treatment, a steady decline in PSA level has been observed (Figure 3).